Alnylam Pharmaceuticals, Inc. vs HCA Health Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288 (market cap $39.89B), while HCA Health Inc trades at $391 (market cap $90.20B). The key difference: HCA Health Inc is far larger — about 2.3× Alnylam Pharmaceuticals, Inc.'s market cap, and HCA Health Inc pays a 0.77% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HCA | |
|---|---|---|
Market Cap | $39.89B | $90.20B |
Sector | Health | Health |
52-Week High | $491.22 | $545.13 |
52-Week Low | $278.09 | $334.32 |
Enterprise Value | $38.15B | $139.10B |
Dividend Yield | — | 0.77% |
Trailing returns across standard periods
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →